Cargando…

Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation

CONTEXT: The mechanism of tetrandrine (TET) in hepatocellular carcinoma (HCC) progression and sorafenib (Sora) chemosensitivity deserves investigation. OBJECTIVE: Using network pharmacology approaches to elucidate the mechanisms of TET in HCC. MATERIALS AND METHODS: CCK-8, colony formation, and flow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Biao, Wei, Sidong, Sun, Jianjun, Zhao, Huibo, Wang, Bing, Chen, Guoyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725900/ https://www.ncbi.nlm.nih.gov/pubmed/34962429 http://dx.doi.org/10.1080/13880209.2021.2017468

Ejemplares similares

Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling
por: Wan, J, et al.
Publicado: (2013)

Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling
por: Tang, Gaofeng, et al.
Publicado: (2022)

Mechanism of Tetrandrine Against Endometrial Cancer Based on Network Pharmacology
por: Shang, Wenqian, et al.
Publicado: (2021)

Progress on structural modification of Tetrandrine with wide range of pharmacological activities
por: Mo, Liuying, et al.
Publicado: (2022)

Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification
por: Li, Jie, et al.
Publicado: (2022)

Unraveling the mechanism of tetrandrine combined with Buyang Huanwu Decoction against silicosis using network pharmacology and molecular docking analyses
por: Li, Yi, et al.
Publicado: (2023)

The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases
por: Gan, Guifang, et al.
Publicado: (2021)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model()()
por: Shi, Shengbin, et al.
Publicado: (2018)

Revisiting Partial Hepatectomy of Large Hepatocellular Carcinoma in Older Patients
por: Chen, Guoyong, et al.
Publicado: (2018)

Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID‐19
por: Heister, Paula M., et al.
Publicado: (2020)

3-hydroxyanthranic acid increases the sensitivity of hepatocellular carcinoma to sorafenib by decreasing tumor cell stemness
por: Gan, Guifang, et al.
Publicado: (2021)

ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma
por: Gu, Jiangning, et al.
Publicado: (2022)

Tetrandrine Derivatives as Promising Antibacterial Agents
por: Calvillo-Páez, Viviana I., et al.
Publicado: (2023)

Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
por: Jiang, Zhonghao, et al.
Publicado: (2023)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE
por: Kimura, Yusuke, et al.
Publicado: (2020)

Simultaneous ABO-incompatible living-donor liver transplantation and splenectomy without plasma exchange in China: Two case reports
por: Chen, Guoyong, et al.
Publicado: (2017)

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma
por: Zhi, Yingru, et al.
Publicado: (2019)

Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway
por: Zhou, Bei, et al.
Publicado: (2019)

Tetrandrine Prevents Neomycin-Induced Ototoxicity by Promoting Steroid Biosynthesis
por: Zhang, Qilei, et al.
Publicado: (2022)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification
por: Xiao, Guanlin, et al.
Publicado: (2023)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2021)

Effect of Tetrandrine against Candida albicans Biofilms
por: Zhao, Lan-Xue, et al.
Publicado: (2013)

Neuroprotective effects of tetrandrine against vascular dementia
por: Lv, Yan-ling, et al.
Publicado: (2016)

Deciphering the pharmacological mechanisms of Chaenomeles Fructus against rheumatoid arthritis by integrating network pharmacology and experimental validation
por: Sun, Mengjia, et al.
Publicado: (2022)

Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway
por: Wang, Jun, et al.
Publicado: (2020)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

A novel class of C14-sulfonate-tetrandrine derivatives as potential chemotherapeutic agents for hepatocellular carcinoma
por: Jiang, Taibai, et al.
Publicado: (2023)

High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma
por: Chen, Guoyong, et al.
Publicado: (2020)

Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy
por: Yu, Borui, et al.
Publicado: (2023)

Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma
por: Stefanovic, Milica, et al.
Publicado: (2016)

FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity
por: Ahmed, Dilruba, et al.
Publicado: (2015)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
por: Li, Xuguang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9808egmk6huctbr3u1qkv63pr1